ArticleFrontiers in immunology2026
Electrophysiological readout of ACTH-related neuroendocrine-immunomodulatory treatment response in infantile epileptic spasms syndrome: suppression of scalp ripple propagation networks.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adrenocorticotropic hormone (ACTH) is a first-line neuroendocrine-immunomodulatory therapy for infantile epileptic spasms syndrome (IESS), but noninvasive electrophysiological markers that objectively reflect treatment-related network changes remain limited. We investigated whether scalp putative ripple propagation network metrics provide markers of adrenocorticotropic hormone-related network response and early relapse risk. Methods: In this retrospective multicenter study, children receiving first-time ACTH therapy were included if paired pre- and post-treatment scalp electroencephalography (EEG) recordings and at least 6 months of follow-up were available. Five-minute artifact-free interictal slow-wave-sleep segments were analyzed. Putative ripple propagation networks were constructed using a time-delay-based method. The primary metrics were post-treatment total network connection strength (total NCS) and its reduction ratio, with ripple count and ripple-count reduction ratio used as rate-based comparators. Results: Sixty-one children were included; 27 achieved acute spasm freedom, and seven of these relapsed within 6 months. Baseline ripple count and network metrics did not distinguish subsequent responders from nonresponders. After adrenocorticotropic hormone therapy, acute responders showed marked suppression of putative ripple propagation network metrics, whereas nonresponders showed reduction in ripple count without comparable reductions in network metrics. Post-treatment total network connection strength and its reduction ratio differentiated acute responders from nonresponders, with areas under the curve (AUC) of 0.902 and 0.899, respectively. In exploratory analyses among acute responders, greater total network connection strength reduction was associated with sustained 6-month spasm freedom, although relapse-related estimates were limited by the small number of events. Conclusion: Scalp putative ripple propagation networks provide a noninvasive electrophysiological readout of ACTH-related network modulation in infantile epileptic spasms syndrome. In contrast to ripple count alone, network connection strength captured whether treatment was accompanied by disruption of propagating high-frequency activity. These findings suggest that total NCS and its reduction ratio may serve as candidate markers of adrenocorticotropic hormone-related neuroendocrine-immunomodulatory therapy response, while their relevance to relapse risk requires prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.